Composition for anticancer adjuvant comprising RIP3 expression promoter as active ingredient, method for screening anticancer adjuvant which promotes RIP3 expression and enhances sensitivity of anticancer agent, and method for monitoring sensitivity of anticancer agent
The present invention relates to a pharmaceutical composition for an anticancer adjuvant comprising a receptor-interacting protein kinase-3 (RIP3) protein expression promotor or activator as an active ingredient. In addition, the present invention provides a method of promoting cancer cell apoptosis, characterized by co-administering an anticancer agent and a RIP3 protein expression promotor or activator to cancer cells. Also, the present invention relates to a method for screening an anticancer adjuvant which promotes RIP3 expression and enhances sensitivity of an anticancer agent, and a method for monitoring sensitivity of an anticancer agent depending on the RIP3 expression. Accordingly, in the case of a patient lacking the expression of RIP3, it is expected to be an effective treatment strategy to pre-treat a demethylating agent to induce the expression of RIP3 and then to use a conventional chemotherapeutic agent. In addition, in chemotherapy, it is anticipated that the present invention may be an effective strategy in screening an anticancer adjuvant which monitors and enhances sensitivity of an anticancer agent.
1. A method for enhancing an anticancer chemotherapeutic drug sensitivity in a subject in need of the anticancer drub treatment, comprising administering an effective amount of a receptor-interacting protein kinase-3 (RIP3) protein expression inducing agent to the subject, wherein the RIP3 protein expression inducing agent is a demethylating agent which is selected from 5-aza-2′-deoxycytidine (5-AD), 5-azacytidine (5-AZA) and RG108, wherein the anticancer chemotherapeutic drug is selected from Doxorubicin, Etoposide, Paclitaxel, Fluorouracil, Camptothecin and Cisplatin.
2. The method of claim 1 , wherein the subject has breast cancer, cervical cancer, glioma, brain cancer, melanoma, lung cancer, bladder cancer, prostate cancer, leukemia, renal cancer, liver cancer, colorectal cancer, pancreatic cancer, gastric cancer, gallbladder cancer, ovarian cancer, lymphoma, osteosarcoma, uterine cancer, oral cancer, bronchial cancer, nasopharyngeal cancer, larynx cancer, skin cancer, blood cancer, thyroid cancer, parathyroid cancer, or ureter cancer.
3. The method of claim 1 , further comprising administering the anticancer chemotherapeutic drug to the subject.